Apremilast is a phosphodiesterase-4 inhibitor taken orally. Little information about its use in
routine clinical practice is available. We aimed to assess treatment safety and persistence …

Apremilast is an oral selective phosphodiesterase-4 inhibitor developed recently for
psoriasis treatment. The aim of this study is to assess the real-life outcomes of use of …

Background: Clinical trial data have shown apremilast, an oral phosphodiesterase-4
inhibitor, to be efficacious and safe for the treatment of psoriasis. However, little real-world …

Introduction: Apremilast is an oral phosphodiesterase inhibitor, approved for moderate to
severe psoriasis in adults. Despite the advancement in dermatology, and the introduction of …

Apremilast is a novel oral phosphodiesterase‐4 inhibitor approved for treatment of plaque
psoriasis and psoriatic arthritis in Japan in December 2016. We have treated a substantial …

Background Apremilast is a novel oral phosphodiesterase‐4 inhibitor approved for psoriasis
treatment. Randomized trials have documented its efficacy and safety, but data on real …

Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, was effective in clinical trials in
patients with moderate plaque psoriasis (affected body surface area [BSA] 5% to 10%) …

Background: Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor used for the
treatment of moderate to severe psoriasis. Long-term data on the effectiveness and drug …

Background: Apremilast is a new oral drug for the treatment of moderate to severe plaque
psoriasis that reduces inflammation by inhibiting phosphodiesterase 4. Its efficacy and safety …

Psoriasis is a chronic, inflammatory, immune‐mediated disease of the skin and joints.
Plaque psoriasis is the most common clinical phenotype of psoriasis. Apremilast is an oral …